@RickOrford
YouTube
Avg. Quality
72
Success Rate
26.92
Analysis
442
Correct
119
Fail
246
Pending
75
Ineffective
0
Total Quality
Score
If You Had Traded on This Analysis…
Fail
PFE
Long Entry
26.6650
2026-02-19
21:01 UTC
Target
35.0000
Fail
26.0000
In 3 Months
Risk/Reward
1 : 13
Turn Signals into Profit
Join Tahlil Plus Pro to unlock full performance history, live alerts, and AI-backed risk tools.
Start Free
Final PnL
-2.49%
P/L: —
Turn Signals into Profit
Join Tahlil Plus Pro to unlock full performance history, live alerts, and AI-backed risk tools.
Start Free
Pfizer's stock shows recent upward momentum, having reached a new 52-week high. While the company's revenue saw a slight year-over-year decline, its adjusted earnings and core business operations remain stable and profitable. The company's consistent dividend payments and conservative valuation contribute to its appeal as a stable, income-generating stock. Analyst consensus remains a "Moderate Buy" with a high target price of $35, suggesting potential upside despite slower near-term growth compared to high-growth tech stocks.
